The HER2 (human epidermal growth factor receptor 2) gene is part of a family of genes that play roles in regulating cell growth. The protein it makes is a tyrosine kinase growth factor receptor that a number of normal tissues express and which probably has a role in normal cell function, regulating growth and proliferation.
The British health secretary Patricia Hewitt has ordered a fast-track assessment of Herceptin, a drug which has shown great promise in treating the early stages of breast cancer.
Unless things change breast cancer patient Barbara Clark will probably have to sell her house to pay for an expensive drug called Herceptin.
High-risk breast cancer patients do not appear to have a higher risk of relapse than the general breast cancer population during the first two years after diagnosis, unless their cancer has spread to more than 10 axillary lymph nodes, Italian researchers reported at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.
A targeted drug shown to improve the outcome of certain breast cancer patients may be of use in the treatment of advanced cases of bladder cancer, according to new research led by the University of Michigan Comprehensive Cancer Center.
New hope has been given to thousands of women living in dread of the return of an aggressive form of breast cancer.
In a study published recently in the Proceedings of the National Academy of Sciences (USA), a team of Weizmann Institute scientists have demonstrated how the right combination might form a web that destroys the cancer cell's communication network, ultimately demobilizing the cell.
A study comparing, for the first time, breast cancers from Nigeria, Senegal and North America has found that women of African ancestry are more likely to be diagnosed with a more virulent form of the disease than women of European ancestry.
Lung cancer patients who have never smoked are more likely than smokers to harbor one of two genetic mutations that researchers at UT Southwestern Medical Center have now linked to the disease.
Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.
Kaiser Permanente researchers are presenting results of a large epidemiologic study of a unique breast cancer test at the 27th Annual San Antonio Breast Cancer Symposium. The KP study shows the test can identify patients with early stage disease who are at low risk of breast cancer death at 10-years.
Six months of treatment with celecoxib (Celebrex) in women at risk of developing breast cancer results in the reduction of estrogen receptor expression in breast cells, a research team at The University of Texas M. D. Anderson Cancer Center has found.
Researchers seeking to direct cancer-killing immune cells against the deadliest brain tumors have three new targets that show promise in laboratory studies and in a Phase I patient trial, according to two articles in the July 15 issue of the journal Cancer Research.
Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.
The approval is based on study results which showed that for women with HER2-positive breast cancer, the combination of Herceptin and Taxotere significantly improved median life expectancy by more than one-third (31 months with Herceptin plus Taxotere vs. 22 months for Taxotere alone).
A new study has found a possible mechanism for tamoxifen resistance in breast cancer and provides evidence that another cancer drug--gefitinib (Iressa)--may be able to restore tamoxifen's anticancer activity.
University of North Carolina molecular biologist Charles Perou has identified the pattern of genes that characterize a biologically distinct subtype of estrogen receptor negative breast tumor.
A pair of studies at UCLA's Jonsson Cancer Center that takes laboratory science to the patients' bedside found that combining the molecularly targeted therapy Herceptin with a specific chemotherapy combination resulted in significant tumor response rates and longer relapse-free periods in women with an aggressive form of advanced breast cancer.